Thank you for sharing your thoughts. Will miss you. One parting question regarding your first substack article on SAGE? How do you interpret the zuranolone data from Japan? Small study admittedly, but data appeared clear and convincing for benefit in MDD (in my opinion)
I havent looked at that one specifically but the broader Zuranolone data for MDD makes the profile pretty clear. It likely only works in depression if there is also anxiety present (their own data showed as much). It's also has a low durability of effect as well as somnolence and tolerance/withdrawal issues. So really, it's very benzo-like.
Thanks for all your blogs. Wishing you the best in your new job!
I very much appreciated your thoughts & general analysis both here and on X, so wish you well in future endeavours.
Thanks, feel free to reach out via Twitter DM anytime!
Thank you for sharing your thoughts. Will miss you. One parting question regarding your first substack article on SAGE? How do you interpret the zuranolone data from Japan? Small study admittedly, but data appeared clear and convincing for benefit in MDD (in my opinion)
I havent looked at that one specifically but the broader Zuranolone data for MDD makes the profile pretty clear. It likely only works in depression if there is also anxiety present (their own data showed as much). It's also has a low durability of effect as well as somnolence and tolerance/withdrawal issues. So really, it's very benzo-like.
Makes sense. Thank you, and best wishes.
Thank you!